AB-3028 for Prostate Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called AB-3028 to determine its safety and effectiveness for individuals with a specific type of prostate cancer that has spread and no longer responds to hormone therapy. The treatment is administered as a single dose through an IV. The trial seeks participants diagnosed with metastatic castration-resistant prostate cancer who have tried at least one other prostate cancer treatment and have a specific marker visible on a scan. Participants should have a progressive form of prostate cancer that persists despite previous treatments. As a Phase 1 trial, this research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive it.
Is there any evidence suggesting that AB-3028 is likely to be safe for humans?
Research is investigating the safety of AB-3028 for treating a type of prostate cancer that has spread and is resistant to standard hormone therapy. As the trial is in its early stages, the main goal is to assess patient tolerance to the treatment. These initial studies closely monitor any side effects or health issues.
AB-3028 is a new treatment, and similar treatments have shown safety for similar conditions. This trial aims to determine the right dose and identify any potential problems. Researchers closely monitor participants to ensure their safety, noting any side effects to improve the treatment.
In summary, the trial is carefully designed to test the safety of AB-3028. Although complete data is not yet available, the study will provide important information about patient tolerance to the treatment.12345Why do researchers think this study treatment might be promising?
AB-3028 is unique because it targets prostate cancer in a novel way by being administered as a single intravenous dose, which is different from the standard treatments like hormone therapy, surgery, or radiation that often require repeated sessions or ongoing administration. Researchers are particularly excited about AB-3028 because it might reduce the treatment burden on patients, potentially offering a more convenient and less invasive option. Additionally, the hope is that AB-3028 could work effectively even in cases where other treatments are less successful, offering new hope for patients with advanced or resistant forms of prostate cancer.
What evidence suggests that AB-3028 might be an effective treatment for prostate cancer?
Research has shown that AB-3028, the treatment under study in this trial, might aid patients with advanced prostate cancer unresponsive to other treatments. In early lab studies, AB-3028 demonstrated strong effects against cancer similar to human prostate cancer. Specifically, it helped patients live longer at lower doses than usual. This treatment is a type of CAR T cell therapy, which uses specially modified immune cells to more effectively attack cancer cells. Early results suggest it could be a promising option for patients whose cancer hasn't improved with other treatments.12367
Are You a Good Fit for This Trial?
This trial is for adults over 18 with metastatic castration-resistant prostate cancer (mCRPC) who have had prior treatment with an androgen receptor pathway inhibitor. They must show PSMA+ on a PET scan, have measurable or evaluable disease, and their organs must function well.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single intravenous infusion of AB-3028
Follow-up
Participants are monitored for safety, tolerability, and response after treatment
What Are the Treatments Tested in This Trial?
Interventions
- AB-3028
Trial Overview
AB-3028, a new type of T cell therapy designed to target cancer cells, is being tested in this Phase 1/2 trial. The study aims to assess the safety and effectiveness of AB-3028 in patients with mCRPC at multiple centers.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Patients receive a single dose of AB-3028 intravenously on day 0.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Arsenal Biosciences, Inc.
Lead Sponsor
Citations
AB-3028, a Programmable Circuit T Cell Therapy in ...
The purpose of this study is to test the safety and efficacy of AB-3028 cells in subjects with metastatic castration-resistant prostate cancer. This treatment ...
256 Preclinical development of AB-3028, a logic-gated ...
AB-3028 exhibited anti-tumor efficacy in the PC3 indication specific xenograft model and provided a survival benefit at doses 4-fold lower ...
AB-3028 / ArsenalBio - Prostate Cancer
AB-3028: Dual-targeting sequential AND logic gated CAR T cell for potential mCRPC therapeutic (SITC 2025) - "Importantly, we also describe the normal ...
256 Preclinical development of AB-3028, a logic-gated ...
... AB-3028, a logic-gated engineered CAR T cell product intended for the treatment of metastatic castration-resistant prostate cancer (mCRPC) ...
AB-3028 - Drug Targets, Indications, Patents
... Efficacy of AB-3028 in Patients With Castration Resistant Prostate Cancer (CRPC). 100 Clinical Results associated with AB-3028. Login to view ...
AB-3028, a Programmable Circuit T Cell Therapy ...
Outcome Measure, Measure Description, Time Frame. Safety and tolerability of AB-3028, To assess safety and tolerability of increasing dose levels of AB-3028 ...
Pipeline • Arsenal Bio
AB-3028 is intended for patients with metastatic castration-resistant prostate cancer. It uses a similar therapeutic approach to AB-1015 and AB-2100, and ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.